

**FOR IMMEDIATE RELEASE CONTACT:**

**Matthew D. Carrington**  
**205-972-0770**  
**carrington@transmolecular.com**

**TransMolecular Broadens Patent Portfolio for Lead Oncology  
Products with Fifth Issued U.S. Patent**

**BIRMINGHAM, Ala. (November 17, 2004)** - TransMolecular, Inc. today announced the issuance of U.S. Patent No. 6,667,156 related to the use of its peptide therapeutics based on chlorotoxin, a small peptide derived from scorpion venom, for the diagnosis and treatment of neuroectodermal tumors. "We are very excited about this fifth issued U.S. patent granted to TransMolecular, which expands our patent portfolio to include both composition of matter and multiple methods of use claims for our novel cancer peptide therapeutics", said Matthew A. Gonda, Ph.D. President and CEO. "Chlorotoxin is a versatile molecule with potential therapeutic opportunities across several tumor types, as well as having potential utility in diagnostic imaging applications when conjugated with certain radioisotopes, because it targets a shared and validated mechanism of action."

**ABOUT TRANSMOLECULAR, INC.**

TransMolecular is a privately held biotechnology company committed to discovering, developing and commercializing novel and proprietary products to diagnose and treat diseases having inadequate pharmaceutical alternatives. The Company's cancer products are based on a 100% chemically synthesized 36 amino acid peptide derived from a naturally occurring protein found in scorpion venom. The Company's lead product, 131I-TM-601 for recurrent glioma, successfully completed a Phase I/II multi-center clinical trial and has started patient enrollment for a larger Phase II multi-center North American clinical trial in Q4 2004. The Company's second most advanced cancer product, TM-701 for treating peripheral solid tumors, is in preclinical development with an IND submission scheduled for 2005. In addition to its cancer program, the Company has a chronic pain program that targets a sodium ion channel called Nav1.9, selectively expressed in the peripheral nervous system. The Company's corporate offices and research laboratories are located in Birmingham, Alabama. For more information, visit [www.transmolecular.com](http://www.transmolecular.com).